Press Release

June 30, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai - 400 001 G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 SCRIP CODE: 543748 SYMBOL: AARTIPHARM Dear Sir/Madam, Sub: Press Release by the Company Ref: Regulation 30 of SEBI (LODR) Regulations, 2015 (Listing Regulations’) Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release dated June 30, 2026 titled "Aarti Pharmalabs Limited inaugurates its new state-of-the-art additional manufacturing block at Tarapur Unit 5, Maharashtra to expand its production capacity”. The Press Release is also available on the website of the Company i.e. www.aartipharmalabs.com Please take the same on your records. Thanking you, Yours faithfully, For AARTI PHARMALABS LIMITED JEEVAN MONDKAR COMPANY SECRETARY AND LEGAL HEAD ICSI M. NO. A22565 Encl.: a/a. Aarti Pharmalabs Limited inaugurates its new state-of-the-art additional manufacturing block at Tarapur Unit 5, Maharashtra to expand its production capacity We are pleased to inform you that the company has inaugurated an additional manufacturing block located at Tarapur, MIDC, Plot No. L-28/29/99. The company has successfully obtained all the necessary permissions and approvals to start the facility. This block has a total capacity of 3600 TPA for Xanthine derivatives manufacturing, taking our total capacity to 9600 TPA, thereby placing us amongst top 3 Xanthine derivatives manufacturers globally. Commenting on this milestone, Mr. Rashesh Gogri, Chairman of Aarti Pharmalabs, said: “This is a significant milestone which represents a big leap forward for our company, expanding our production capabilities and strengthening our ability to serve our business partners. Trial production has been initiated, and the facility will be ramped up for optimum utilization in the next few quarters.” The inauguration event witnessed the presence of the Senior Management team, alongside the dedicated members of the Aarti Pharmalabs team. This new manufacturing block emphasizes a commitment towards the company’s growth and capability development to cater to large customers’ needs. About Aarti Pharmalabs Limited Aarti Pharmalabs Limited (NSE: AARTIPHARM | BSE: 543748) is a prominent Indian pharmaceutical and nutraceutical manufacturer with a global presence. It focuses on innovation, sustainability, and is one of the leaders in the pharmaceutical and nutraceutical domain. The company specializes in offering comprehensive CDMO/CMO services for small molecule drug substances, catering to clinical and commercial phase projects for innovator pharma companies, with dedicated facilities for HPAPIs, corticosteroids, cytotoxic, and oncology products. It also offers generic APIs and Intermediates, and is globally amongst top producers of Xanthine derivatives. Plant Location: Aarti Pharmalabs Limited, Unit-V, Plot L-28/29/99, Tarapur MIDC, Boisar, Maharashtra, India, Pin 401506.